Cargando…

Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer

AIM: This study aimed to determine the prognostic factors influencing the overall survival (OS) of Iranian women with epithelial ovarian cancer (EOC). METHODS: Information about newly diagnosed patients with confirmed EOC at Motahari Clinic, Shiraz, Iran, from January 1, 2001, to December 31, 2016,...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalafi-Nezhad, Abolfazl, Ebrahimi, Vahid, Ahmadpour, Fatemeh, Momtahan, Mozhdeh, Robati, Minoo, Saraf, Zahra, Ramzi, Mani, Jowkar, Zahra, Ghaffari, Parvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049748/
https://www.ncbi.nlm.nih.gov/pubmed/32161497
http://dx.doi.org/10.2147/CMAR.S237073
_version_ 1783502505385132032
author Khalafi-Nezhad, Abolfazl
Ebrahimi, Vahid
Ahmadpour, Fatemeh
Momtahan, Mozhdeh
Robati, Minoo
Saraf, Zahra
Ramzi, Mani
Jowkar, Zahra
Ghaffari, Parvin
author_facet Khalafi-Nezhad, Abolfazl
Ebrahimi, Vahid
Ahmadpour, Fatemeh
Momtahan, Mozhdeh
Robati, Minoo
Saraf, Zahra
Ramzi, Mani
Jowkar, Zahra
Ghaffari, Parvin
author_sort Khalafi-Nezhad, Abolfazl
collection PubMed
description AIM: This study aimed to determine the prognostic factors influencing the overall survival (OS) of Iranian women with epithelial ovarian cancer (EOC). METHODS: Information about newly diagnosed patients with confirmed EOC at Motahari Clinic, Shiraz, Iran, from January 1, 2001, to December 31, 2016, was retrospectively reviewed and analyzed. Cox-adjusted proportional hazards (PH) and stratified Cox (SC) models were used to determine the potential prognostic factors. RESULTS: The mean (±SD) age at the diagnosis of 385 patients with EOC was 49.0 (±13.2) years old. Early-stage EOC (ESEOC) and advanced-stage EOC (ASEOC) were diagnosed in 34.3% and 65.7% of the total patients, respectively. The median (95% CI) OS was 35 (28−41) months. For ESEOC patients, a stage II-tumor led to a lower OS in the multivariable analysis compared to a lower stage tumor (P= 0.025). For ASEOC patients, age≥65 years at diagnosis (P=0.008) led to a lower OS. ASEOC patients with 2–5 parities (P=0.014) and >5 parity (P=0.001) demonstrated better OS than nulliparous women. CONCLUSION: Patients with ESEOC, higher tumor stage was associated with a shorter OS. The age at diagnosis harmed the OS of patients with ASEOC. More than one parity improved OS in ASEOC patients.
format Online
Article
Text
id pubmed-7049748
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70497482020-03-11 Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer Khalafi-Nezhad, Abolfazl Ebrahimi, Vahid Ahmadpour, Fatemeh Momtahan, Mozhdeh Robati, Minoo Saraf, Zahra Ramzi, Mani Jowkar, Zahra Ghaffari, Parvin Cancer Manag Res Original Research AIM: This study aimed to determine the prognostic factors influencing the overall survival (OS) of Iranian women with epithelial ovarian cancer (EOC). METHODS: Information about newly diagnosed patients with confirmed EOC at Motahari Clinic, Shiraz, Iran, from January 1, 2001, to December 31, 2016, was retrospectively reviewed and analyzed. Cox-adjusted proportional hazards (PH) and stratified Cox (SC) models were used to determine the potential prognostic factors. RESULTS: The mean (±SD) age at the diagnosis of 385 patients with EOC was 49.0 (±13.2) years old. Early-stage EOC (ESEOC) and advanced-stage EOC (ASEOC) were diagnosed in 34.3% and 65.7% of the total patients, respectively. The median (95% CI) OS was 35 (28−41) months. For ESEOC patients, a stage II-tumor led to a lower OS in the multivariable analysis compared to a lower stage tumor (P= 0.025). For ASEOC patients, age≥65 years at diagnosis (P=0.008) led to a lower OS. ASEOC patients with 2–5 parities (P=0.014) and >5 parity (P=0.001) demonstrated better OS than nulliparous women. CONCLUSION: Patients with ESEOC, higher tumor stage was associated with a shorter OS. The age at diagnosis harmed the OS of patients with ASEOC. More than one parity improved OS in ASEOC patients. Dove 2020-02-26 /pmc/articles/PMC7049748/ /pubmed/32161497 http://dx.doi.org/10.2147/CMAR.S237073 Text en © 2020 Khalafi-Nezhad et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Khalafi-Nezhad, Abolfazl
Ebrahimi, Vahid
Ahmadpour, Fatemeh
Momtahan, Mozhdeh
Robati, Minoo
Saraf, Zahra
Ramzi, Mani
Jowkar, Zahra
Ghaffari, Parvin
Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer
title Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer
title_full Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer
title_fullStr Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer
title_full_unstemmed Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer
title_short Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer
title_sort parity as a prognostic factor in patients with advanced-stage epithelial ovarian cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049748/
https://www.ncbi.nlm.nih.gov/pubmed/32161497
http://dx.doi.org/10.2147/CMAR.S237073
work_keys_str_mv AT khalafinezhadabolfazl parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer
AT ebrahimivahid parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer
AT ahmadpourfatemeh parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer
AT momtahanmozhdeh parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer
AT robatiminoo parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer
AT sarafzahra parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer
AT ramzimani parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer
AT jowkarzahra parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer
AT ghaffariparvin parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer